The EndoEase™ platform leverages a variety of peptides to enhance the delivery of large molecule drugs through different administration routes. Supported by machine learning, the platform identifies the most effective peptide combinations, enabling the creation of non-invasive, painless delivery systems that optimize drug absorption and efficiency.
Large molecule drugs face challenges crossing biological barriers via oral, transdermal, intranasal, and inhalation routes. EndoEase™ platform solves this by creating temporary, painless openings between cells, allowing the drugs to enter systemic circulation. After delivery, the openings close, restoring the cells to their original state.
Enables the painless delivery of large molecule drugs, which overcomes the limitations of traditional needle-based administration.
By bypassing liver metabolism, it reduces protein degradation from extreme pH levels in the stomach and intestines, preventing drug activity loss from enzyme and microbial metabolism, thus enhancing bioavailability.
Enables large molecule drugs to enter systemic circulation through the skin or mucous membranes, enhancing bioavailability and reducing dosage while minimizing side effects.
Large molecule drugs currently struggle to cross the nasal mucosal barrier. However, with the EndoEase™ platform and metered dose spray devices, we can develop nasal sprays that facilitate drug absorption through the nasal mucosa, allowing them to reach the bloodstream and deliver their therapeutic benefits.
As the body’s primary defense, the skin’s tightly packed stratum corneum restricts penetration to molecules smaller than 500 Da. However, transdermal formulations developed with the EndoEase™ platform enable large molecule drugs to efficiently penetrate the skin, be absorbed, and enter systemic circulation, greatly improving their bioavailability.